Thelansis

 Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type of non-Hodgkin lymphoma (NHL). It is a diverse malignancy characterized by molecular changes, morphology, clinical behavior, and treatment response variations. Due to its aggressive nature, DLBCL exhibits rapid growth and tends to affect both nodal and extranodal sites, such as the stomach, testis, and CNS. Approximately 25-30% of DLBCL patients experience relapse, with 10% facing refractory disease, resulting in a poor prognosis for relapsed/refractory (R/R) DLBCL. The majority of DLBCL relapses typically manifest within two years following diagnosis. However, some DLBCL patients still encounter relapses after five years, primarily associated with favorable International Prognostic Index (IPI) scores, limited-stage disease, and extranodal involvement at diagnosis. Double-hit lymphomas (DEL) are more prevalent among R/R DLBCL patients (45%) in comparison to primary DLBCL (20-35%), and this association correlates with...